Stocksigma LogoStocksigma Logo

Fredun Pharmaceuticals Reports Zero Deviation in Preferential Issue Proceeds for Q2 FY27

Fredun Pharmaceuticals confirmed nil deviation in utilizing ₹128.78 crore raised via preferential issue as of 30th Sep'26

Fredun Pharmaceuticals Reports Zero Deviation in Preferential Issue Proceeds for Q2 FY27

Fredun Pharmaceuticals Ltd · Others (Uncategorized) · 14 Nov 2026, 8:57 pm

Fredun Pharmaceuticals Reports Zero Deviation in Preferential Issue Proceeds for Q2 FY27 Fredun Pharmaceuticals confirmed nil deviation in utilizing ₹128.78 crore raised via preferential issue as of 30th Sep'26. Management-certified cumulative utilization stood at ₹97.56 crore, while Monitoring Agency CARE Ratings reported ₹101.34 crore. The ₹3.78 crore variance stems from accounting treatment differences regarding funds parked in cash credit accounts. Key cumulative deployments include ₹57.07 crore for working capital, ₹20.34 crore for strategic reserves, ₹11.50 crore for brand marketing, ₹6.98 crore for capex, ₹3.95 crore for contingencies, and ₹1.50 crore for R&D.

Original exchange filing (PDF)

More announcements from Fredun Pharmaceuticals Ltd

All Fredun Pharmaceuticals Ltd announcements